# Study Evaluating ReFacto AF in Severe Hemophilia A

> **NCT00037544** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** ReFacto AF

## Key facts

- **NCT ID:** NCT00037544
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2004-08
- **Final completion:** 2004-08
- **Target enrollment:** — (—)
- **Last updated:** 2008-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00037544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00037544, "Study Evaluating ReFacto AF in Severe Hemophilia A". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00037544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*